Infliximab in patients with active ankylosing spondylitis: experience at Hospital Nacional Edgardo Rebagliati Martins

Descripción del Articulo

Infliximab is effective in treating patients with ankylosing spondylitis (AS). However, its cost makes its indiscrimate use prohibitive. Objective: To determine whether an induction regimen with infliximab remained effective over time in a group of patients with active AS. Design: Exposed only. Sett...

Descripción completa

Detalles Bibliográficos
Autores: Montero, Manuel, García-Poma, Augusto, Chung, Cecilia, Chávez, José, Segami, María I.
Formato: artículo
Fecha de Publicación:2007
Institución:Universidad Nacional Mayor de San Marcos
Repositorio:Revistas - Universidad Nacional Mayor de San Marcos
Lenguaje:español
OAI Identifier:oai:ojs.csi.unmsm:article/1228
Enlace del recurso:https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/1228
Nivel de acceso:acceso abierto
Materia:Espondilitis anquilosante
agentes antirreumáticos
enfermedades reumáticas
Spondylitis
ankylosing
antirheumatic agents
rheumatic diseases
id REVUNMSM_36563bbb477893d3641000bc0f505d6c
oai_identifier_str oai:ojs.csi.unmsm:article/1228
network_acronym_str REVUNMSM
network_name_str Revistas - Universidad Nacional Mayor de San Marcos
repository_id_str
spelling Infliximab in patients with active ankylosing spondylitis: experience at Hospital Nacional Edgardo Rebagliati MartinsInfliximab en pacientes con espondilitis anquilosante activa: experiencia en el Hospital Nacional Edgardo Rebagliati MartinsMontero, ManuelGarcía-Poma, AugustoChung, CeciliaChávez, JoséSegami, María I.Espondilitis anquilosanteagentes antirreumáticosenfermedades reumáticasSpondylitisankylosingantirheumatic agentsrheumatic diseasesInfliximab is effective in treating patients with ankylosing spondylitis (AS). However, its cost makes its indiscrimate use prohibitive. Objective: To determine whether an induction regimen with infliximab remained effective over time in a group of patients with active AS. Design: Exposed only. Setting: Rheumatology Service, Hospital Nacional Edgardo Rebagliati. Participants: Patients with active and refractory ankylosing spondylitis. Interventions: Infliximab, administered at weeks 0, 2 and 6. One patient received doses of 3 mg/kg and the remaining patients received 5 mg/kg of infliximab. All patients continued their treatment with sulfasalazine. Main outcome measures: We determined the proportion of patients achieving ASAS 20, ASAS 40 and Bath ankylosing spondylitis disease activity index - BASDAI 50 at last assessment (median of 55 weeks). Results: At last observation, five patients (71,4%) had a sustained ASAS 20 response. Four (57%) and three (43%) patients remained responders according to the BASDAI 50 and ASAS 40 respectively.Three patients (43%) relapsed, with mean time of 26,6 weeks. No serious adverse events were observed. Conclusions: The infusion of three doses of infliximab is effective to control disease activity in patients with refractory AS. In some patients, effectiveness remained for a prolonged period of time.Infliximab es un medicamento efectivo en el tratamiento de pacientes con espondilitis anquilosante (EA) activa. Sin embargo, debido a su alto costo, su uso indiscriminado es prohibitivo. Objetivo: Evaluar si un régimen de inducción con infliximab es efectivo en pacientes con EA activa. Diseño: Sólo expuestos. Lugar: Servicio de Reumatología del Hospital Nacional Edgardo Rebagliati. Participantes: Pacientes con espondilitis anquilosante activa refractaria. Intervenciones: infliximab a las 0, 2 y 6 semanas. Un paciente recibió dosis de 3 mg/kg y los restantes 5 mg/kg de infliximab. Todos los pacientes continuaron recibiendo sulfasalazina. Principales medidas de resultados: Se determinó la proporción de pacientes que alcanzaron mejoría de acuerdo a los criterios ASAS 20, ASAS 40 y BASDAI 50, en la última evaluación (mediana de 55 semanas). Resultados: En la última evaluación, cinco pacientes (71,4%) presentaban respuesta ASAS 20 sostenida. Cuatro (57%) y tres (43%) de los pacientes alcanzaron BASDAI 50 y ASAS 40, respectivamente. Tres pacientes (43%) recayeron en un tiempo promedio de 26,6 semanas. No se observó efectos adversos serios. Conclusiones: La infusión de tres dosis de infliximab es efectiva para controlar la actividad de la enfermedad de los pacientes con EA refractaria a AINEs y en algunos pacientes controla la enfermedad por periodos prolongados de tiempo.Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana2007-06-18info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/122810.15381/anales.v68i2.1228Anales de la Facultad de Medicina; Vol. 68 No. 2 (2007); 175-180Anales de la Facultad de Medicina; Vol. 68 Núm. 2 (2007); 175-1801609-94191025-5583reponame:Revistas - Universidad Nacional Mayor de San Marcosinstname:Universidad Nacional Mayor de San Marcosinstacron:UNMSMspahttps://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/1228/1033Derechos de autor 2007 Manuel Montero, Augusto García-Poma, Cecilia Chung, José Chávez, María I. Segamihttps://creativecommons.org/licenses/by-nc-sa/4.0info:eu-repo/semantics/openAccessoai:ojs.csi.unmsm:article/12282020-04-14T21:44:42Z
dc.title.none.fl_str_mv Infliximab in patients with active ankylosing spondylitis: experience at Hospital Nacional Edgardo Rebagliati Martins
Infliximab en pacientes con espondilitis anquilosante activa: experiencia en el Hospital Nacional Edgardo Rebagliati Martins
title Infliximab in patients with active ankylosing spondylitis: experience at Hospital Nacional Edgardo Rebagliati Martins
spellingShingle Infliximab in patients with active ankylosing spondylitis: experience at Hospital Nacional Edgardo Rebagliati Martins
Montero, Manuel
Espondilitis anquilosante
agentes antirreumáticos
enfermedades reumáticas
Spondylitis
ankylosing
antirheumatic agents
rheumatic diseases
title_short Infliximab in patients with active ankylosing spondylitis: experience at Hospital Nacional Edgardo Rebagliati Martins
title_full Infliximab in patients with active ankylosing spondylitis: experience at Hospital Nacional Edgardo Rebagliati Martins
title_fullStr Infliximab in patients with active ankylosing spondylitis: experience at Hospital Nacional Edgardo Rebagliati Martins
title_full_unstemmed Infliximab in patients with active ankylosing spondylitis: experience at Hospital Nacional Edgardo Rebagliati Martins
title_sort Infliximab in patients with active ankylosing spondylitis: experience at Hospital Nacional Edgardo Rebagliati Martins
dc.creator.none.fl_str_mv Montero, Manuel
García-Poma, Augusto
Chung, Cecilia
Chávez, José
Segami, María I.
author Montero, Manuel
author_facet Montero, Manuel
García-Poma, Augusto
Chung, Cecilia
Chávez, José
Segami, María I.
author_role author
author2 García-Poma, Augusto
Chung, Cecilia
Chávez, José
Segami, María I.
author2_role author
author
author
author
dc.subject.none.fl_str_mv Espondilitis anquilosante
agentes antirreumáticos
enfermedades reumáticas
Spondylitis
ankylosing
antirheumatic agents
rheumatic diseases
topic Espondilitis anquilosante
agentes antirreumáticos
enfermedades reumáticas
Spondylitis
ankylosing
antirheumatic agents
rheumatic diseases
description Infliximab is effective in treating patients with ankylosing spondylitis (AS). However, its cost makes its indiscrimate use prohibitive. Objective: To determine whether an induction regimen with infliximab remained effective over time in a group of patients with active AS. Design: Exposed only. Setting: Rheumatology Service, Hospital Nacional Edgardo Rebagliati. Participants: Patients with active and refractory ankylosing spondylitis. Interventions: Infliximab, administered at weeks 0, 2 and 6. One patient received doses of 3 mg/kg and the remaining patients received 5 mg/kg of infliximab. All patients continued their treatment with sulfasalazine. Main outcome measures: We determined the proportion of patients achieving ASAS 20, ASAS 40 and Bath ankylosing spondylitis disease activity index - BASDAI 50 at last assessment (median of 55 weeks). Results: At last observation, five patients (71,4%) had a sustained ASAS 20 response. Four (57%) and three (43%) patients remained responders according to the BASDAI 50 and ASAS 40 respectively.Three patients (43%) relapsed, with mean time of 26,6 weeks. No serious adverse events were observed. Conclusions: The infusion of three doses of infliximab is effective to control disease activity in patients with refractory AS. In some patients, effectiveness remained for a prolonged period of time.
publishDate 2007
dc.date.none.fl_str_mv 2007-06-18
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/1228
10.15381/anales.v68i2.1228
url https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/1228
identifier_str_mv 10.15381/anales.v68i2.1228
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/1228/1033
dc.rights.none.fl_str_mv https://creativecommons.org/licenses/by-nc-sa/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana
publisher.none.fl_str_mv Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana
dc.source.none.fl_str_mv Anales de la Facultad de Medicina; Vol. 68 No. 2 (2007); 175-180
Anales de la Facultad de Medicina; Vol. 68 Núm. 2 (2007); 175-180
1609-9419
1025-5583
reponame:Revistas - Universidad Nacional Mayor de San Marcos
instname:Universidad Nacional Mayor de San Marcos
instacron:UNMSM
instname_str Universidad Nacional Mayor de San Marcos
instacron_str UNMSM
institution UNMSM
reponame_str Revistas - Universidad Nacional Mayor de San Marcos
collection Revistas - Universidad Nacional Mayor de San Marcos
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1795238242069512192
score 13.871801
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).